Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study.

ABSTRACT:

Background

The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with IPF have ever been exposed to an antifibrotic. Understanding the burden and consequences of the disease and its treatment from the perspective of people living with IPF may facilitate improved education and outreach for them and their providers.

Methods

Qualitative interviews with people living with IPF explored perspectives on the diagnosis and management of IPF. Transcripts were analyzed to derive themes and topics, and illustrative quotes were selected for presentation. Data were developed into a 74-item on-line survey taken by additional people living with IPF. Quantitative

SUBMITTER: Graham CS 

PROVIDER: S-EPMC12060508 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature